drugset / Trial / NCT02601274
Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
A Phase I, open-label, multicenter dose-escalation study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of hmpl-309 in patients with advanced solid tumors
Timeline
- Start
- 2015-04
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped: “the change of clinical development plan”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Theliatinib | Small molecule | 120 mg | Oral |
| Subject | Theliatinib | Small molecule | 160 mg | Oral |
| Subject | Theliatinib | Small molecule | 200 mg | Oral |
| Subject | Theliatinib | Small molecule | 220 mg | Oral |
| Subject | Theliatinib | Small molecule | 300 mg | Oral |
| Subject | Theliatinib | Small molecule | 400 mg | Oral |
| Subject | Theliatinib | Small molecule | 500 mg | Oral |